1.. Introduction
================

Gastric cancer is the fifth most common cancer and third leading cause of cancer mortality in the world, according to the International Agency for Research on Cancer in 2018 ([@b1-ol-0-0-11623]). The morbidity of gastric cancer affected \>1 million in 2018, accounting for 5.7% of new cancer cases globally. Worldwide, gastric cancer mortality is \~783,000, accounting for 8.2% of the total global deaths caused by cancer in 2018 ([@b1-ol-0-0-11623]). Diagnosis of gastric cancer relies on endoscopic examination and analyses of serum biomarkers in the clinical practice ([@b2-ol-0-0-11623]). However, endoscopy cannot be used for large-scale screening, and detection by serum biomarkers lacks sensitivity and specificity ([@b3-ol-0-0-11623]). To date, there is no simple and efficient diagnostic method that allows for the early diagnosis of gastric cancer to improve its prognosis.

Circular RNAs (circRNAs) are a group of single-strand closed-loop RNAs that are derived from back-splicing and are widely found in serum and saliva ([@b4-ol-0-0-11623],[@b5-ol-0-0-11623]). circRNAs serve a regulatory role at the transcriptional and/or post-transcriptional level, but some can only function at the transcriptional level. Previous research has found that biological functions of circRNAs include microRNA (miRNA) sponging, regulation of transcription and translation, and interaction with RNA-binding proteins ([@b4-ol-0-0-11623],[@b6-ol-0-0-11623]--[@b8-ol-0-0-11623]). Additionally, the dysregulation of circRNA expression is suggested to play an important role in the pathogenesis and diagnosis of gastric cancer.

Although little is known about the role of circRNAs in the development of gastric cancer at the molecular level, circRNAs secreted into the extracellular environment can be identified in blood, stool and other body fluids ([@b9-ol-0-0-11623]--[@b12-ol-0-0-11623]). Thus, circRNAs might be used as new potential biomarkers for the diagnosis and therapeutic targeting of gastric cancer.

2.. Biological functions of circRNAs
====================================

circRNAs are abnormally expressed in various cancer types, including gastric cancer ([@b13-ol-0-0-11623]--[@b16-ol-0-0-11623]), such as circCCDC66, circPIP5K1A, circ-ATAD1 are higher expressed, but circMTO1 expression is lower in gastric cancer ([@b17-ol-0-0-11623]--[@b20-ol-0-0-11623]). circRNAs may cause cancer by interacting with tumor-associated miRNAs, proteins and genes, and by participating in pathophysiological activities, including proliferation, invasion and apoptosis ([@b21-ol-0-0-11623]--[@b23-ol-0-0-11623]). CDR1 antisense RNA (CDR1as) is an abundantly expressed circRNA in the mammalian brain with \>70 miRNA (miR)-7 binding sites ([@b24-ol-0-0-11623]). CDR1as/miR-7 is a classical tumor-associated circRNA-miRNA sponge system. CDR1as inhibits miR-7 activity by competing with miR-7, which ultimately upregulates the expression of oncogenes, such as epidermal growth factor receptor, NF-κB, and eventually promotes the development of cancer ([@b25-ol-0-0-11623]).

Overexpression of CDR1as inhibits the proliferation and invasion of glioma, breast cancer, gastric cancer and colorectal cancer ([@b26-ol-0-0-11623]--[@b29-ol-0-0-11623]). By contrast, upregulation of other circRNAs, such as circHIPK3, hsa_circ_001569 and circSCAF11, promotes the development of bladder and colorectal cancers, as well as glioma ([@b30-ol-0-0-11623]--[@b32-ol-0-0-11623]). In addition, abundant exosome circRNAs in the serum differentiate gastric cancer by transmitting a signal to local and remote cells, such as infiltrating immune cells, stromal cells and endothelial cells. These cells are vital components of the tumor microenvironment and enhance tumor growth, angiogenesis and metastasis ([@b33-ol-0-0-11623]). Such circRNAs may be useful for early and specific diagnosis of tumors.

### miRNA sponge

circRNAs can absorb specific miRNAs through numerous miRNA binding sites ([Fig. 1A](#f1-ol-0-0-11623){ref-type="fig"}). Conversely, they may serve as highly efficient sponges with miRNA to inhibit the biological functions of miRNAs and prevent them from binding to their target genes ([@b34-ol-0-0-11623]). For example, Sex-determining region Y, the testis-specific circRNA, inhibits the activity of miR-138 through multiple miR-138 binding sites and potentially regulates expression of miR-138 target genes ([@b35-ol-0-0-11623]). It is speculated that miRNA sponge effects achieved by circRNA formation are a common phenomenon ([@b35-ol-0-0-11623]). circ-CEP85L functions as a sponge of miR-942-5p to suppress expression of its target genes NFKBIA ([@b36-ol-0-0-11623]). In addition, circFGFR4 promotes the differentiation of myoblasts by sponging miR-107 and suppressing its target gene Wnt3 expression ([@b37-ol-0-0-11623]).

### Interaction with RNA-binding proteins (RBPs)

circRNAs are involved in numerous physiological processes by interacting with a variety of RBPs to form RNA-protein complexes, regulating gene transcription and influencing the formation of circRNAs ([Fig. 1B](#f1-ol-0-0-11623){ref-type="fig"}). RBPs affect the expression of downstream target genes and miRNA sponges by competing with miRNAs ([@b6-ol-0-0-11623],[@b7-ol-0-0-11623]). RBPs also act as *trans*-factors to regulate circRNA generation. Modulation of splicing factor muscle blind (MBL) expression affects the biosynthesis of circMBL through specific binding to MBL binding sites within introns of circMBL ([@b38-ol-0-0-11623]). circMBL regulates parental gene expression by binding to its own pre-mRNA flanking introns binding sites at the transcriptional level. circRNAs have a binding site for the enzyme and its substrate, thus it can directly bind to protein or act as a scaffold between two or more proteins. It has been reported that circ-Amotl1 interacts with proto-oncogene c-Myc, STAT3, pyruvate dehydrogenase kinase 1and AKT1 and affects the expression of its target genes by promoting nuclear translocation of these proteins ([@b39-ol-0-0-11623],[@b40-ol-0-0-11623]). In addition, RBPs are also involved in the post-transcriptional regulation of miRNA expression and interact with miRNA regulators by cooperative and competitive inhibition ([@b41-ol-0-0-11623]). Pumilioprotein, a cooperative RBP, promotes miRNA binding to target mRNA, which inhibits protein translation by binding to a specific short sequence in the 3′UTR of target mRNA, leading to altered spatial conformation of mRNA ([@b42-ol-0-0-11623]).

### Regulation of transcription

circRNAs derived from exons are located in the cytoplasm and have an open reading frame (ORF) to drive translation ([Fig. 1C](#f1-ol-0-0-11623){ref-type="fig"}) ([@b43-ol-0-0-11623]). In addition, some circRNA protein translation is initiated after being modified by N^6^-methyladenosine (m^6^A), such as circRNAs initiates the protein translation by recruit YTHDF3 and EIf4G2 through the m^6^A modification site ([@b44-ol-0-0-11623]). circANRIL regulates the expression of INK4/ARF by affecting the binding of ANRIL to polycomb-group complex and inhibiting the transcription of the coding gene INK4 and its variable reading frame genes ([@b45-ol-0-0-11623]). circPABPN1 reduces the translational efficiency of PABPN1 mRNA by competitively binding the RBP human antigen R (HuR) and prevents HuR binding to PABPN1 mRNA ([@b46-ol-0-0-11623]). In addition, a small amount of circRNAGFP participates in the translation process as a template ([@b47-ol-0-0-11623]).

### Regulation of host gene expression

circRNA sequences are highly similar to their homogenous linear mRNA. circRNAs act as positive regulators of the activity of RNA polymerase II (RNA pol II), affecting expression of parental genes and transcription ([Fig. 1D](#f1-ol-0-0-11623){ref-type="fig"}). circEIF3J and circPAIP2, both exon-intron circRNAs (EIciRNAs), interact with U1 small nuclear ribonucleoprotein (snRNP) through RNA-RNA interactions to form EIciRNA-U1 snRNP complexes. This complex interacts with RNA pol II in the promoter region of host genes to *cis*-regulate the expression of its host genes ([@b48-ol-0-0-11623]). Additionally, circ-ITCH has common miRNA binding sites with the 3′ untranslated region of itchy E3 ubiquitin protein ligase (ITCH). circ-ITCH interacts with miR-7, miR-17 and miR-214 to promote the expression of ITCH ([@b49-ol-0-0-11623]).

3.. circRNAs regulate proliferation and progression in gastric cancer
=====================================================================

### circRNAs regulate the proliferation and progression as miRNA sponges in gastric cancer

circRNAs promote malignant cell development, proliferation and metastasis by sponging miRNAs resulting in the dysregulated expression of miRNAs and the disruption of target genes in gastric cancer. Upregulated circPDSS1 expression promotes the expression of NIMA-related kinase 2 (NEK2) in gastric cancer through a miR-186-5p sponge *in vivo* and *in vitro* ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b50-ol-0-0-11623]). Subsequently NEK2, which is associated with cell centrosome and cell cycle in gastric cancer, enhances cell proliferation and cell cycle by regulating cell mitosis in this type of cancer ([@b51-ol-0-0-11623]). circPVT1, a potential oncogenic gene, inhibits the activity of miR-125 and promotes the proliferation of gastric cancer through c-Myc ([@b52-ol-0-0-11623]). In addition, circLARP4 is inversely associated with tumor size and lymph node metastasis in gastric cancer by regulating the target gene large tumor suppressor kinase 1 and Yes-associated protein (YAP) of miR-424, resulting in the inhibition of DNA synthesis, cell proliferation and invasion ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b53-ol-0-0-11623]). circYAP1 inhibits cellular proliferation, invasion and cell cycle by suppressing cyclin dependent kinase inhibitor 1B. Downregulated circYAP1 in gastric cancer is linked to poor prognosis and low 5 year survival rate ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b53-ol-0-0-11623]).

circ_100269 suppresses the p53 signaling pathway by sponging miR-630 to inhibit proliferation and invasion of gastric cancer ([@b54-ol-0-0-11623]). In addition, circ_0027599 sponges miR-101 to inhibit the migration and invasion of gastric cancer by targeting pleckstrin homology-like domain family A member 1 gene ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b55-ol-0-0-11623]). These differential expressions of circRNAs in the different aforementioned cancers play crucial but different roles in determining cell fate, inducing tumor-suppressive or oncogenic effects by acting as a sponge to multiple different miRNAs, forming a circRNA-miRNA-mRNA axis ([@b50-ol-0-0-11623]--[@b55-ol-0-0-11623]). Thus, circRNAs have the ability to participate in many physiological and pathological processes, suggesting that the regulation of circRNAs could offer a potential therapeutic window for gastric cancer.

### circRNAs regulate the proliferation and progression through the RBP sponge in gastric cancer

circRNAs not only function as miRNA sponges to regulate miRNA expression, but also serve important roles in regulating protein production ([@b56-ol-0-0-11623]). circRNAs affect the proliferation and metastasis potential of malignant cells, including gastric cancer cells, by directly interacting with proteins or binding to the miRNA-acting factor to regulate specific downstream target genes ([@b57-ol-0-0-11623]).

Downregulated circPVRL3 also promotes the proliferation of gastric cancer by promoting protein encoding ([@b58-ol-0-0-11623]). It might play a role in the assembling of RBP complexes by binding to AGO2, FUS RNA-binding protein, lin-28 homolog A, polypyrimidine tract binding protein and eukaryotic translation initiation factor 4A3. In addition, circPVRL3 contains internal ribosome entry site, ORF and m^6^A modifications, these modifications initiate the protein translation by recruiting ribosomes ([@b59-ol-0-0-11623],[@b60-ol-0-0-11623]). The translational products may exert specific biological effects or interfere with protein-protein interactions to affect tumor progression ([@b44-ol-0-0-11623],[@b61-ol-0-0-11623]). Another study reported that circFAT1(e2), located in cytoplasm and nucleus of gastric cancer cells, is downregulated in gastric cancer ([@b62-ol-0-0-11623]). circFAT1(e2) directly binds to Y-box binding protein-1 (YBX1) for DNA- and RNA-binding in the nucleus. Upregulated circFAT1(e2) inhibits the growth of gastric cancer by suppressing the expression of three targeted genes of YBX1 (epidermal growth factor receptor, MET proto-oncogene and cell division cycle 25A).

Results from these studies suggest that the stability of circRNA-protein interaction might act as 'scaffolding molecules' in gastric cancer. Consequently, circRNAs acting as scaffolding molecules for protein complexes and network functional modules can modulate protein-protein interactions. circRNAs might work as sequence targeting elements, affecting the function of downstream target genes by simultaneously binding to RBPs.

### circRNAs control the proliferation and progression of gastric cancer cells via regulating cellular metabolism

Cell glycolytic activity, including in aerobic conditions, is more active in cancer cells compared with normal cells, process known as the Warburg effect ([@b63-ol-0-0-11623]). In addition, tumor cells exhibit abnormal fatty acid and amino acid metabolism ([@b64-ol-0-0-11623]). Recent studies demonstrated that circRNAs are closely related to tumor metabolism and these are able to regulate gastric cancer metabolism through miRNA ([@b65-ol-0-0-11623]--[@b67-ol-0-0-11623]).

Upregulated circNRIP1 expression promotes the proliferation, invasion and migration of gastric cancer through activating AKT1/mTOR cell pathway by sponging miR-149-5p ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b65-ol-0-0-11623]). circNRIP1 promotes anabolic activities and prevents metabolic decomposition by maintaining energy homeostasis, suggesting that circNRIP1 plays a crucial role in the regulation of tumor metabolism ([@b66-ol-0-0-11623],[@b67-ol-0-0-11623]).

In gastric cancer, ciRS-133 regulates substance metabolism and organic metabolism through PR domain-containing 16(PRDM16), enhancing the Warburg effect. ciRS-133 accelerates oxygen consumption and glucose consumption of brown fat cells, promoting white adipose tissue (WAT) burning through enhancing the expression of PRDM16 by adsorbing miR-133 in gastric cancer cells ([Fig. 2](#f2-ol-0-0-11623){ref-type="fig"}) ([@b68-ol-0-0-11623]). Consequently, such effects are known to cause weight loss and systemic inflammation in patients with poor prognosis. Moreover, knockdown of ciRS-133 reduces cancer cachexia, decreasing oxygen consumption and glucose expenditure in mouse animal models ([@b68-ol-0-0-11623]). Thus, circRNAs contribute to cancer-associated cachexia and metabolic disorder by sponging miRNA to regulate WAT browning.

4.. circRNAs have a potential clinical value in gastric cancer
==============================================================

### Potential application of circRNAs in the diagnosis of gastric cancer

Several studies have demonstrated that circRNAs are differentially expressed in gastric cancer, as summarized in [Table I](#tI-ol-0-0-11623){ref-type="table"}. circRNAs are widely present in blood and gastric juice, and may have potential value for diagnosis ([@b9-ol-0-0-11623]--[@b12-ol-0-0-11623]). Therefore, circRNAs may work as novel biomarker-based screening tools for gastric cancer diagnosis and evaluation.

In gastric cancer, circ_102958 is closely associated to tumor, node, metastasis (TNM) cancer staging, but inversely associated to age, gender, tumor diameter and differentiation degree in lymph node metastasis ([@b69-ol-0-0-11623]). In addition, receiver operating characteristic curve analysis indicated that circ_102958 has a high diagnostic value. Together, these features suggested that circ_102958 may be a biomarker for early diagnosis of gastric cancer.

Owing to the lack of clinical symptoms and detection methods at the early stages of gastric cancer, the analysis of gastric juice could be advantageous for the detection of this type of cancer ([@b70-ol-0-0-11623]). For instance, circ_0014717 is downregulated in gastric juice of chronic atrophic gastritis. Individuals with chronic atrophic gastritis are at high risk of gastric cancer ([@b71-ol-0-0-11623]). This implies that circ_0014717 may be used for early screening of gastric cancer ([@b72-ol-0-0-11623]). In addition, circ_0000181 is downregulated in the plasma of patients with gastric cancer and is positively associated with the differentiation of gastric cancer cells and the level of carcinoembryonic antigen (CEA), which is a well-known gastric cancer biomarker ([@b73-ol-0-0-11623]). In addition, the specificity and sensitivity of hsa_circ_0000181 is higher than CEA and carbohydrate antigen19-9 in screening gastric cancer, suggesting that hsa_circ_0000181 may be a reliable plasma-based biomarker ([@b74-ol-0-0-11623]).

### circRNAs as a prognosis biomarker in gastric cancer

circRNAs can potentially be used as a biomarker for the prognosis and the evaluation of treatment efficacy in gastric cancer. It has been demonstrated that circ_0000467 is highly expressed in tissue and plasma samples of patients with gastric cancer associated with a poor prognosis. Cox multivariate analysis showed that circ_0000467 might be an ideal independent prognostic factor ([@b75-ol-0-0-11623]). In addition, a previous study reported that the determination of prognostic factors in gastric cancer using circ_0000467 along with TNM stage is more accurate compared to that using TNM stage alone ([@b75-ol-0-0-11623]).

The expression of circ_KIAA1244 in plasma of patients with gastric cancer is lower than that in healthy patients without gastric cancer, which is inversely associated with TNM stage and lymph node metastasis, as well as a shorter overall survival. This is supported by univariate and multivariate analysis, which demonstrated that the expression of circ_KIAA1244 may be used as an independent prognostic indicator of the overall survival in patients with gastric cancer ([@b76-ol-0-0-11623]).

### circRNA as a therapeutic target biomarker in gastric cancer

More recently, with the development of molecular biology and in-depth pathogenesis studies, the mechanistic function of circRNAs in metabolic and signal transduction pathways has also been investigated for gastric cancer. ciRS-7 possesses about 70 binding sites for miR-7 and has significant functions in several types of tumors, including gastric cancer, where it is highly expressed ([@b77-ol-0-0-11623]). ciRS-7 is able to enhance proliferation and migration of gastric cancer cells by upregulating PTEN/PI3K/AKT signaling pathway through sponging of miR-7 ([@b78-ol-0-0-11623]). Overexpression of ciRS-7 is also shown to promote the growth of xenograft tumors *in vivo* exhibiting a promising therapeutic value for gastric cancer ([@b78-ol-0-0-11623]). Therefore, developing inhibitors that can efficiently target ciRS-7 may be an important approach for therapy.

Highly expressed circ_0067997 promotes tumor growth in gastric cancer by sponging miR-515-5p, which results in the regulation of x-linked inhibitor of apoptosis (XIAP) expression ([@b79-ol-0-0-11623],[@b80-ol-0-0-11623]). Suppressing circ_0067997 by siRNA blocks a variety of apoptosis-related pathways and reduces cell viability, colony formation, proliferation and invasion of gastric cancer cell lines *in vitro*. circ_0067997 siRNAs treated MGC-803 cells inhibits the growth of tumors *in vivo* compared with si-NC treated cells, also suggesting a potential therapeutic target ([@b81-ol-0-0-11623]).

Finally, using Gene Ontology functional term and Kyoto Encyclopedia of Genes and Genomes signaling pathway analyses, gastric cancer was found to be linked to circRNAs in several important physiological processes, such as extracellular matrix degradation, binding to cell adhesion molecules and reaction with transforming growth factor β ([@b82-ol-0-0-11623]).

Data from these studies demonstrated that circRNAs may contribute to the occurrence and development of gastric cancer, and its application in tumor therapy presents a valuable prospect. circRNAs may also be used as a therapeutic target for inhibiting tumor proliferation and metastasis.

5.. Future prospects
====================

Increasing evidence demonstrates that the expression of circRNAs affect the development and progression of gastric cancer and may exhibit great potential in diagnosis, prognosis and treatment of gastric cancer. Research within the mechanistic function of circRNAs is an emerging scientific field with an enormous potential. The differential expression of circRNAs in gastric cancer compared to non-cancer samples enables the use of these circRNAs as potential biomarkers ([@b41-ol-0-0-11623],[@b83-ol-0-0-11623],[@b84-ol-0-0-11623]). circRNAs are have a stable structure and are widely expressed in various body fluids, including blood, saliva and gastric fluid ([@b9-ol-0-0-11623]--[@b12-ol-0-0-11623]). In addition, RNA sequencing and reverse transcription-quantitative PCR have made the detection of circRNAs more convenient and accurate than proteins as detection time is shorter, smaller amount of sample is required and the sensitivity is higher. Numerous circRNAs are highly enriched in the blood compared with the corresponding linear RNAs. Moreover, the expression of circRNAs in cancer tissue is higher than in precancerous tissue derived exosomes ([@b85-ol-0-0-11623]), which is consistent with another study showing that the levels of circ-KIAA1244 in plasma and plasma exosomes are similar ([@b76-ol-0-0-11623]). Therefore, circRNAs in extracellular exosomes represent the ideal candidates as reliable biomarkers for prognosis and diagnosis in gastric cancer. However, at present, circRNAs can only be used in combination with other biomarkers for cancer diagnosis, and the clinical application of circRNAs still requires further investigation and optimization. Although there are many studies about circRNAs, there no current standardized methodology for detecting circRNAs. Also, to the best of our knowledge there is no detailed study about the application of circRNAs as biomarkers for malignant cells, particularly regarding cost and the specificity and sensitivity for detecting cancer cells.

The biological functions of several circRNAs may be utilized to explore the underlying mechanism of circRNAs during the development of gastric cancer. Despite many specific circRNAs reportedly expressed in gastric cancer, the features of circRNAs, including their biogenesis, degradation, location and function, remain to be explored. Therefore, comprehensive studies are required to determine the function and molecular mechanisms of circRNAs in gastric cancer. Moreover, further understanding of the relationship between circRNAs and gastric cancer may reveal the complex regulatory networks of carcinogenesis and accelerate the clinical application of circRNAs in prognosis, diagnosis and therapy of gastric cancer.

6.. Conclusions
===============

In the present review, the biological functions and molecular mechanisms of circRNAs were examined, and the clinical values of circRNAs with an emphasis on gastric cancer were summarized. Although numerous circRNAs have been identified, only a small amount of functional circRNAs has been elucidated, and most studies on circRNAs have focused on their regulation of cancer development through interactions with miRNAs and RBPs. In the future, the mechanistic study of its roles in genomic and mRNA transcription needs to be further explored. As circRNAs are known to be stable in different body fluids, including blood, circRNAs may act as ideal biomarkers and therapeutic targets for gastric cancer.
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![Biological functions of circRNAs. A pre-mRNA is back-spliced, producing three different types of circRNA, including ciRNAs, ecirRNAs and EIciRNA. The biological functions of circRNAs are regulated by different mechanisms. (A) miRNA sponge. circRNAs absorb specific miRNA to regulate the biological function of miRNA, affecting miRNA target gene expression. (B) RBP sponge. circRNAs interact with a variety of RBPs to form RNA-protein complexes, regulating their cellular localization and activity. (C) Translate proteins. Some circRNAs can be translated into proteins that exert specific biological effects and affect tumor progression. (D) Promote gene transcription. ciRNAs and EIciRNAs promote the transcription of their parental genes by acting as positive regulators of Pol II activity. AGO, protein argonaute; circRNAs, circular RNAs; ciRNAs, intronic circular RNAs; ecirRNAs, exonic circular RNAs; EIciRNA, exon-intron circular RNAs; miRNAs, micro RNAs; Pol II, RNA polymerase II; RBPs, RNA binding proteins.](ol-20-01-0465-g00){#f1-ol-0-0-11623}

![Roles of circRNAs in gastric cancer. circRNAs function as sponges for the indicated miRNAs, which regulate the respective target genes to promote or inhibit tumor proliferation, invasion and metastasis. circRNA, circular RNA; LARP4, La ribonucleoprotein 4; LATS1, large tumor suppressor kinase 1; miR, microRNA; NEK2, NIMA related kinase 2; NRIP1, nuclear receptor interacting protein 1; p27^kip1^, cyclin dependent kinase inhibitor 1B; PDSS1, decaprenyl diphosphate synthase subunit 1; PHLDA1, pleckstrin homology like domain family A member 1; PRDM16, PR/SET domain 16; YAP1, Yes associated protein 1.](ol-20-01-0465-g01){#f2-ol-0-0-11623}

###### 

circRNAs and their functions in gastric cancer.

  Author, year           circRNA                             Research model in GC            Expression change                                Functions          Regulatory network; pathway                                                                   (Refs.)
  ---------------------- ----------------------------------- ------------------------------- ------------------------------------------------ ------------------ --------------------------------------------------------------------------------------------- ------------------------
  Tian *et al*, 2018     Hsa_circ_0003159                    Tissue                          Downregulation                                   Biomarker                                                                                                        ([@b99-ol-0-0-11623])
  Li *et al*, 2017       Hsa_circ_0001649                    Tissue and serum                Downregulation                                   Biomarker                                                                                                        ([@b86-ol-0-0-11623])
  Shao *et al*, 2017     Hsa_circ_0014717                    Tissue and gastric juice        Downregulation                                   Biomarker                                                                                                        ([@b72-ol-0-0-11623])
  Xie *et al*, 2018      Hsa_circ_0074362                    Tissue and cell lines           Downregulation                                   Biomarker                                                                                                        ([@b95-ol-0-0-11623])
  Li *et al*, 2018       Hsa_circ_0001017/Hsa_circ_0061276   Tissue and plasma               Downregulation                                   Biomarker                                                                                                        ([@b90-ol-0-0-11623])
  Li *et al*, 2015       Hsa_circ_002059                     Tissue and plasma               Downregulation                                   Biomarker                                                                                                        ([@b92-ol-0-0-11623])
  Zhao *et al*, 2018     Hsa_circ_0000181                    Tissue and plasma               Downregulation                                   Biomarker                                                                                                        ([@b74-ol-0-0-11623])
  Huang *et al*, 2017    Hsa_circ_0000745                    Tissue and plasma               Downregulation                                   Biomarker          Sponge to miRNA                                                                               ([@b88-ol-0-0-11623])
  Chen *et al*, 2017     Hsa_circ_0000190                    Tissue and plasma               Downregulation                                   Biomarker                                                                                                        ([@b100-ol-0-0-11623])
  Tang *et al*, 2019     Hsa_circ_0130810 (circ-KIAA1244)    Tissue, cell lines and plasma   Downregulation                                   Biomarker                                                                                                        ([@b76-ol-0-0-11623])
  Lu *et al*, 2017       Hsa_circ_0006633                    Tissue, cell lines and plasma   Downregulation in tissue/Upregulation in cells   Biomarker                                                                                                        ([@b93-ol-0-0-11623])
  Sun *et al*, 2018      Hsa_circ_0000520                    Tissue, cell lines and plasma   Downregulation                                   Biomarker          Nine miRNAs and nine candidate mRNA (AGO1, AGO2, AGO3, Fus, FMRP, CAPRIN1, DGCR8, PTB, HuR)   ([@b94-ol-0-0-11623])
  Fang *et al*, 2017     Hsa_circ_0058246                    Tissue                          Upregulation                                     Biomarker                                                                                                        ([@b91-ol-0-0-11623])
  Zhang *et al*, 2019    Hsa_circ_0067997                    Tissue and cell lines           Upregulation                                     Biomarker          Hsa_circ_0067997/miR-515-5p/XIAP                                                              ([@b79-ol-0-0-11623])
  Wei *et al*, 2019      Hsa_circ_102958                     Tissue and cell lines           Upregulation                                     Biomarker          Sponge to five miRNAs                                                                         ([@b69-ol-0-0-11623])
  Li *et al*, 2017       Hsa_circ_104916                     Tissue and cell lines           Downregulation                                   Tumor suppressor   EMT                                                                                           ([@b87-ol-0-0-11623])
  Zhang *et al*, 2017    Hsa_circ_100269                     Tissue and cell lines           Downregulation                                   Tumor suppressor   Sponge to miR-630                                                                             ([@b54-ol-0-0-11623])
  Liu *et al*, 2019      circLARP4                           Tissue and cell lines           Downregulation                                   Tumor suppressor   circLARP4/miR-424-5p/LATS1                                                                    ([@b41-ol-0-0-11623])
  Li *et al*, 2017       Hsa_circ_0000096                    Tissue and cell lines           Downregulation                                   Tumor suppressor   Regulating cyclin D1, CDK6, MMP-2 and MMP-9                                                   ([@b89-ol-0-0-11623])
  Liu *et al*, 2018      circYAP1                            Tissue and cell lines           Downregulation                                   Tumor suppressor   circYAP1/miR-367-5p/p27 axis                                                                  ([@b53-ol-0-0-11623])
  Sun *et al*, 2018      Has_circ_0066779 (circPVRL3)        Tissue and cell lines           Downregulation                                   Tumor suppressor   Sponge to nine miRNAs                                                                         ([@b58-ol-0-0-11623])
  Li *et al*, 2017       circHIPK3                           Tissue and cell lines           Downregulation                                   Tumor suppressor   circHIPK3/miR-124/miR-29b                                                                     ([@b30-ol-0-0-11623])
  Zhong *et al*, 2018    Hsa_circ_0000993                    Tissue and cell lines           Downregulation                                   Tumor suppressor   Hsa_circ\_ 0000993/miR-214-5p/ATL2                                                            ([@b97-ol-0-0-11623])
  Wei *et al*, 2018      circZFR                             Tissue and cell lines           Downregulation                                   Tumor suppressor   circZFR/miR-130a/miR-107; PTEN                                                                ([@b98-ol-0-0-11623])
  Wang *et al*, 2018     Hsa_circ_0027599                    Tissue and cell lines           Downregulation                                   Tumor suppressor   Hsa_circ_0027599/miR-101-3p.1/PHLDA1                                                          ([@b55-ol-0-0-11623])
  Fang *et al*, 2019     Hsa_circ_0001461 \[circFAT1(e2)\]   Tissue and cell lines           Downregulation                                   Tumor suppressor   circFAT1(e2)/miR-548g/YBX1                                                                    ([@b62-ol-0-0-11623])
  Chen *et al*, 2017     circPVT1                            Tissue and cell lines           Upregulation                                     Tumor promoter     circPVT1/miR-125/E2F2                                                                         ([@b52-ol-0-0-11623])
  Pan *et al*, 2018      ciRS-7 (CDR1as)                     Tissue and cell lines           Upregulation                                     Tumor promoter     CiRS-7/miR-7/PTEN/PI3K; AKT                                                                   ([@b78-ol-0-0-11623])
  Rong *et al*, 2018     Hsa_circ_0066444                    Tissue and cell lines           Upregulation                                     Tumor promoter     Sponge to 5 miRNAs and 15 corresponding target mRNAs                                          ([@b96-ol-0-0-11623])
  Zhang *et al*, 2019    Hsa_circ_0010522 (ciRS-133)         Tissue and plasma               Upregulation                                     Tumor promoter     ciRS-133/miR-133/PRDM16                                                                       ([@b68-ol-0-0-11623])
  Ouyang *et al*, 2019   circPDSS1                           Tissue and cell lines           Upregulation                                     Tumor promoter     circPDSS1/miR-186-5p/NEK2                                                                     ([@b50-ol-0-0-11623])
  Shen *et al*, 2019     Hsa_circ_001569                     Tissue and cell lines           Upregulation                                     Tumor promoter     Hsa_circ_001569/miR-145/ NR4A2                                                                ([@b103-ol-0-0-11623])
  Zhou *et al*, 2018     Hsa_circ_0023642                    Tissue and cell lines           Upregulation                                     Tumor promoter     EMT                                                                                           ([@b101-ol-0-0-11623])
  Zhang *et al*, 2019    circNRIP1                           Tissue and cell lines           Upregulation                                     Tumor promoter     circNRIP1/miR-149-5p/AKT1/mTOR                                                                ([@b65-ol-0-0-11623])
  Lu *et al*, 2019       Hsa_circ_0000467                    Tissue, cell lines and plasma   Upregulation                                     Tumor promoter                                                                                                   ([@b75-ol-0-0-11623])
  Sun *et al*, 2018      circ-SFMBT2                         Tissue, cell lines and plasma   Upregulation                                     Tumor promoter     circ-sFMBT2/miR-182-5p/CReB1                                                                  ([@b102-ol-0-0-11623])

circRNAs, circular RNAs; GC, gastric cancer; miR, microRNA.
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